Maze Therapeutics, Inc. 4

Harold Bernstein, President, R&D & CMO of Maze Therapeutics, sold 10,295 shares of common stock for about $269,000 in tax-related sales tied to RSU vesting.

On September 2 and 3, 2026, Harold Bernstein, President, R&D & CMO of Maze Therapeutics, Inc., executed multiple open-market sales of the company’s common stock solely to cover tax withholding obligations arising from restricted stock unit vesting. The transactions comprised sales of 4,481 shares at a weighted average price of $26.3760 and 625 shares at $27.1211 on September 2, followed by 5,130 shares at $26.0133 and 59 shares at $25.7800 on September 3, with all trades executed on a discretionary (direct) basis. In total, he sold 10,295 shares for an aggregate value of approximately $269,000, leaving him with direct ownership of 9,705 shares of Maze Therapeutics common stock after these tax-related sales.

Filing Facts

CIK

1842295

Ticker

MAZE

Form

4

Source Type

fda

Accession

0002050172-26-000034

Alert Tier

6